Site Map | Changes / Renewal | Terms of Use

| 2011 | 2010 | 2009 | 2007 | 2006 | 2005 | 2004 | 2003 |   December 22 Toray, Japan Tobacco and Torii Terminate the Joint Development of nalfurafine hydrochloride (“TRK-820”) for Pruritus Associated with Liver Disease in Japan February 7 Torii Pharmaceutical to Launch Hyperkalemia Improvement Agent, KAYEXALATE® DRYSYRUP 76% January 28 ALK and Torii enter into an exclusive license agreement for allergy immunotherapy products in Japan January 29 Torii and Toray terminate Co-Promotion of Hemoperfusion absorption column "Toraymyxin" for removing endotoxin March 23 Launch of REMITCH® CAPSULES 2.5 μg , new oral antipruritus drug January 21 Manufacturing and marketing approval for REMITCH® CAPSULES 2.5 µg , oral antipruritus drug, in Japan January 13 Torii Pharmaceutical to Solely Market Antiemetic Drugs "Serotone® I.V. Injection 10 mg" and "Serotonereg® Tablets 10 mg" December 18 Torii Pharmaceutical and Minophagen Pharmaceutical to Phase Out Basic Trade Agreement October 31 Future Marketing and Distribution Organization for Dovonex® Ointment for the Treatment of Psoriasis Vulgaris September 26 JT and Torii Sign Licensing Agreement with Keryx for Development and Commercialization of Hyperphosphatemia Drug in Japan July 6 Torii Pharmaceutical to Launch Antifungal Agent for External Use, "ZEFNART SOLUTION 2%", in Japan June 29 Torii, Toray starts to Co-Promote Hemoperfusion absorption Column "Toraymyxin" for removing endotoxin November 28 New Drug Application of Antipruritic Agent "TRK-820" for the Treatment of Severe Pruritus in Hemodialysis Patients in Japan September 4 Toray, JT, Torii Agree to Co-Develop and Market TRK-820 Antipruritus Drug for Hepatic Disease Patients in Japan August 3 Conclusion of an Agreement over Co-promotion of Dops® for the Treatment of Orthostatic Hypotension March 31 Conclusion of Co-marketing Agreement for Dovonex® Ointment for the Treatment of Psoriasis Vulgaris April 22 JT Group to Merge Pharmaceutical Production Facilities April 8 JT and Torii Pharmaceutical to Launch New HIV Treatment Drugs in Japan March 16 Toray, Japan Tobacco, Torii Pharmaceutical Agree to Co-Develop and Market New Antipruritus Drug in Hemodialysis Patients in Japan April 5 JT and Torii Pharmaceutical to Launch New HIV Treatment Drug in Japan April 5 Transfer of Marketing Right for TachoComb March 25 Notice for Dissolution of a Subsidiary January 30 Outside Contact of Distribution Work November 11 Notice Concerning Completion of Acquisition Company's Own Shares Through ToSTNet-2 November 10 Notice Concerning Acquisition of Company's Own Shares Through ToSTNet-2 September 1 Termination of Co-promotion Agreement exchanged on Zaditen® with Novaltis Pharma K.K. May 8 Notice Concerning Acquisition of the Company's Own Shares in the Market May 8 Notice of Change of Representative Director January 28 The Results of Limited-Period Voluntary Early Retirement Program